GSK To Pay $229M To Settle US Avandia Suits

Law360, Los Angeles (July 24, 2013, 8:13 PM EDT) -- GlaxoSmithKline PLC plans to pay $229 million to settle lawsuits relating to the development and marketing of controversial diabetes drug Avandia, along with a separate action in Louisiana, the research-based pharmaceutical and health care company confirmed Wednesday.

The British company has been entangled for years in litigation over the drug, which has been linked to heart attacks, liver failure and other injuries. The company said in a quarterly earnings statement that it had reached the settlement in principle with the attorneys general of Louisiana, Mississippi, South Carolina,...
To view the full article, register now.